Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Quantitating progression in ALS.

Mamede de Carvalho1, Manuel Scotto, Arminda Lopes

  • 1Department of Neurology, Hospital de Santa Maria, Laboratory of Electromyography, Centro de Estudos Egas Moniz, Faculty of Medicine, Institute of Molecular Medicine, Lisbon, Portugal. mamedemg@mail.telepac.pt

Neurology
|May 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced spinal motoneuron excitability as a marker of motor neuron dysfunction in primary lateral sclerosis.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2026
Same author

Environmental Personal Exposure Clusters to Investigate Multiple Sclerosis and Amyotrophic Lateral Sclerosis Progression.

Studies in health technology and informatics·2026
Same author

Interleukin-6 in ALS: metabolic mediator or marker of ventilatory decline?

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

The Cat is Out of the Bag: Confronting False-Positive Risks in Amyotrophic Lateral Sclerosis Clinical Trials.

Neurology·2026
Same author

Large-scale exome analyses reveal new rare variant contributions in amyotrophic lateral sclerosis.

Nature genetics·2026
Same author

Quantification of Tongue Motor Dysfunction in Amyotrophic Lateral Sclerosis Using a Smartphone-Based Task and Deep Learning.

Sensors (Basel, Switzerland)·2026
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

This study found that the neurophysiologic index (NI) and motor unit number estimation (MUNE) reliably track ALS progression. These measures, along with abductor digiti minimi muscle strength, showed significant changes over 12 months.

Area of Science:

  • Neurology
  • Neurophysiology

Background:

  • Amyotrophic lateral sclerosis (ALS) progression assessment requires reliable clinical and neurophysiologic markers.
  • Existing methods may have limitations in sensitivity and consistency.

Purpose of the Study:

  • To prospectively evaluate the value of clinical and neurophysiologic measurements for assessing ALS progression.
  • To determine the reliability and rate of change for motor unit number estimation (MUNE) and the neurophysiologic index (NI).

Main Methods:

  • Prospective study design.
  • Inclusion of clinical assessments and neurophysiologic measurements.
  • Correlation analysis between MUNE, NI, and abductor digiti minimi (ADM) muscle strength (maximal voluntary isometric contraction force [MVIC-ADM]).
  • Assessment of changes at 3, 6, and 12 months.

Related Experiment Videos

Main Results:

  • MUNE and NI demonstrated significant correlation with MVIC-ADM.
  • Both MUNE and NI proved to be reliable measures.
  • The NI exhibited lower variability compared to MUNE.
  • MUNE, NI, and MVIC-ADM showed the highest rates of change, indicating sensitivity to progression.
  • The NI is identified as a potentially valuable new neurophysiologic measurement for tracking ALS.

Conclusions:

  • MUNE and NI are reliable and sensitive neurophysiologic tools for monitoring ALS progression.
  • The neurophysiologic index (NI) shows promise as a new, reliable measurement with lower variation.
  • These findings support the use of NI and MUNE in clinical trials and patient monitoring for ALS.